Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-005647-14-GB

Enrollment

120

Registered

2008-02-22

Start date

2009-03-16

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with osteoporosis or Paget's disease of bone MedDRA version: 9.1 Level: LLT Classification code 10031282 Term: Osteoporosis MedDRA version: 9.1 Level: LLT Classification code 10033362 Term: Paget's disease

Interventions

Trade Name: Bonviva Pharmaceutical Form: Injection* Other descriptive name: IBANDRONIC ACID MONOSODIUM SALT, MONOHYDRATE Concentration unit: mg milligra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Due to receive or currently receiving or have received intravenous bisphosphonates for the treatment of osteoporosis or paget's disease of bone Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Unable to give informed consent Poor venous access

Design outcomes

Primary

Measure	Time frame
Main Objective: to determine whether the presence acute phase reaction to aminobisphosphonates can be predicted by exanination of the gamma delta T cells of a patient;Secondary Objective: ;Primary end point(s): donation of blood sample(s) for analysis of gamma delta t cell response	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026